Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
63.737,31
-0,24%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ VistaGen Therapeutics Inc (VTGN) VistaGen Therapeutics Inc (VTGN) Notizie

VistaGen Therapeutics Inc

VTGN
4,55
0,14 (3,17%)
04 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
25/4/202414:30BWVistagen Announces Positive Results from Phase 2A Pilot..
09/4/202414:30BWVistagen to Present at the 2024 Anxiety and Depression..
01/4/202414:30BWVistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol..
11/3/202413:30BWVistagen to Present at Stifel 2024 Virtual CNS Days
07/3/202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
28/2/202414:30BWVistagen to Present at TD Cowen 44th Annual Health Care..
15/2/202400:18EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202422:51EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14/2/202414:56EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202422:52EDGAR2Form S-3 - Registration statement under Securities Act of..
13/2/202422:33EDGAR2Form 8-K - Current report
13/2/202422:25EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/2/202422:20BWVistagen Reports Fiscal 2024 Third Quarter Financial Results..
06/2/202414:30BWVistagen to Report Fiscal Year 2024 Third Quarter Financial..
03/1/202423:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202423:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202423:09EDGAR2Form 8-K - Current report
27/12/202314:30BWVistagen Receives Notice from European Patent Office of..
09/11/202322:44EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202322:42EDGAR2Form 8-K - Current report
09/11/202322:30BWVistagen Provides Corporate Update and Reports Fiscal 2024..
08/11/202314:30BWVistagen to Present at Stifel 2023 Healthcare Conference
07/11/202314:30BWVistagen to Present Positive Fasedienol Phase 3 Data and..
07/11/202303:46EDGAR2Form 8-K/A - Current report: [Amend]
06/11/202322:27EDGAR2Form 8-K - Current report
06/11/202314:00BWVistagen To Report Second Quarter Financial Results and Host..
04/11/202301:14EDGAR2Form 3 - Initial statement of beneficial ownership of..
26/10/202322:13EDGAR2Form 8-K - Current report
16/10/202322:37EDGAR2Form SC 13G - Statement of acquisition of beneficial..
16/10/202322:01EDGAR2Form SC 13G - Statement of acquisition of beneficial..
06/10/202322:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/10/202322:05EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
05/10/202322:47EDGAR2Form SC 13G - Statement of acquisition of beneficial..
05/10/202314:30BWVistagen to Present at Jefferies Inaugural Biotech CNS/Neuro..
04/10/202322:07EDGAR2Form 8-K - Current report
03/10/202322:40EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
02/10/202313:30BWVistagen Announces Pricing of $100 Million Underwritten..
02/10/202313:15EDGAR2Form 8-K - Current report
29/9/202322:26EDGAR2Form 8-K - Current report
12/9/202314:30BWVistagen Announces Positive Results from Exploratory Phase..
08/9/202323:27EDGAR2Form 8-K - Current report
05/9/202315:00BWVistagen and Fuji Enter Exclusive Negotiation Agreement for..
23/8/202319:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/8/202319:08EDGAR2Form 3 - Initial statement of beneficial ownership of..
22/8/202314:40EDGAR2Form 8-K - Current report
22/8/202314:30BWVistagen Appoints Cindy Anderson as Chief Financial Officer
Apertura: 4,47 Min: 4,31 Max: 4,55
Chiusura: 4,41

La tua Cronologia

NASDAQ
VTGN
VistaGen Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network